DAI-NIPPON-PRINTING
16.12.2020 07:08:08 CET | Business Wire | Press release
Amid increased awareness of hygiene and safety as the Covid-19 pandemic continues to spread around the world, Dai Nippon Printing Co., Ltd. (DNP) (TOKYO: 7912) has developed a new transparent display screen that can be operated in a touchless format, by merely moving a hand over a motion sensor. By removing the need to make direct contact with the cursor, the newly developed screen will be positioned as a countermeasure to the spread of Covid-19.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201215006213/en/
https://www.youtube.com/watch?v=h5QKhThRtWw
A liquid crystal (LC) light control film is attached to a transparent screen facilitating a variety of video expressions on a single screen, from standard displays to augmented reality (AR) driven effects, including those where vivid images appear to hang in the air.
For further information about LC light control film, please visit:
https://www.dnp.co.jp/eng/news/detail/1191596_2453.html
For further information about transparent screens that can be used in bright location please visit:
https://www.dnp.co.jp/eng/news/detail/10158931_2453.html
.
[Background]
As health and safety awareness grows, more users are calling for the development of products with antibacterial and antiviral functions, along with those that can be used in a touchless format.
At the same time, we have also recently seen a heightened focus on AR technology that supports consumer activities by imposing artificially created information over existing real world information. In answer to these dual developments, DNP has created a touchless display screen capable of giving expression to AR-driven spatial effects that enhance the immersive impact of presentations.
This has been achieved through the successful combination of, 1, a motion sensor that detects the operator’s movements, 2, an LC light control film that produces a clear image, and 3, a transparent screen that heightens the AR effect.
[Display Features]
- The in-built motion sensor detects the movements of users and operators, and by activating the LC light control film, which is integrated into the transparent screen, makes it possible to display clearer images.
- Bringing the palm of the hand closer to the screen activates the sensor, which causes the cursor to appear. The cursor can then be maneuvered in a touchless format via hand movements, including clicking on screen buttons to set actions into motion by bending the index finger towards the screen.
- DNP’s proprietary LC light control film leverages coating technology to achieve a precise coating of the LC. And, by controlling the direction of the LC using electrical power, it is possible to block or transmit light with high precision, enabling the display of diverse and clear images.
- The DNP transparent screen is produced by applying a precision lens to a large film substrate using advanced optical lens design technology and fine shaping technology.
- The background can be viewed by making the integrated LC light control film transparent then projecting an image upon it. In this way, it is possible to achieve an AR effect in which images appear to hand in the air.
[Looking Ahead]
We anticipate a variety of usage scenarios for the touchless transparent screen, such as in vending and ticket machines, along with uses as the reception desks at hotels and companies. In addition, DNP will further develop and propose LC light control films and transparent screens targeting touchless displays as a countermeasure against infectious diseases.
[About DNP]
DNP is one of the world’s largest comprehensive printing companies, providing a diverse portfolio of products and services to about 20,000 corporate clients worldwide. Since we were founded in 1876, we have consistently innovated new products and processes, and have successfully integrated proprietary printing and information technologies to branch out into various fields, including packaging, decorative materials, display components, and electronic devices. DNP continues to take on the challenge of new business fields, including those related to the environment, energy, and life sciences. Our aim is to become a principal provider of solutions to a variety of problems by developing and combining new technologies.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201215006213/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Andersen Consulting tilføjer samarbejdsfirmaet TechSparq25.10.2026 06:09:00 CET | Pressemeddelelse
Andersen Consulting udvider sine kompetencer inden for teknologi og forretningstransformation gennem en samarbejdsaftale med TechSparq, en amerikansk virksomhed, der kombinerer strategi, commerce engineering og ai med praktisk implementering. TechSparq er et digitalt konsulenthus, der tilbyder strategi- og rådgivningstjenester, commerce engineering samt tjenester inden for ai og agentbaseret handel til virksomheder inden for detailhandel og forbrugsgoder, luksus og mode samt e-handel og direkte salg til forbrugere. Virksomheden har hovedkontor i Oregon og kombinerer strategisk planlægning med praktisk implementering for at hjælpe kunderne med at udvikle deres digitale initiativer, kundeoplevelse og driftsmodeller. "Vi etablerede vores virksomhed for at bygge bro mellem dem, der udvikler strategien, og dem, der har ansvaret for at føre den ud i livet," udtalte Dedrick Boyd, stifter af og administrerende direktør for TechSparq. "Vores samarbejde med Andersen Consulting giver os mulighed
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press release
Potential first-in-class GPC3 x 4-1BB bispecific achieves a 36% confirmed response rate at Phase 3 dose and favorable safety profile in heavily pretreated liver cancerBrain-penetrant PRMT5 inhibitor shows promising antitumor and CNS activity in the largest publicly shared MTAP-deficient datasetFirst clinical data of CEA-targeting ADC demonstrates encouraging and sustained responses in CEAhigh NSCLC BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to dise
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
